Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis
Frontiers in Oncology · 29.05.2026 · 16
DOI: 10.3389/fonc.2026.1849765 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 29.05.2026. Verfasst von Ziqian Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This study examined whether pretreatment neutrophil-to-lymphocyte ratio (NLR) was associated with survival outcomes and treatment response in breast cancer patients treated with neoadjuvant chemotherapy.
Methods
PubMed, EMBASE, Web of Science, and the Cochrane Library were searched for eligible studies published up to April 2026. Using Stata 18.0 and Review Manager 5.4, pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were synthesized to determine the relationship of pretreatment NLR with overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and pathologic complete response (pCR).
Results
Fifty-six studies involving 16,539 patients were included. Elevated pretreatment NLR was significantly associated with worse OS (HR = 1.89, 95% CI 1.48–2.41; P<0.00001), DFS (HR = 1.79, 95% CI 1.45–2.23; P<0.00001), and RFS (HR = 1.89, 95% CI 1.17–3.05; P = 0.01), as well as a reduced likelihood of achieving pCR (OR = 0.50, 95% CI 0.40–0.64; P<0.00001). These findings remained stable in sensitivity analyses restricted to multivariable-adjusted estimates.
Conclusion
Elevated pretreatment NLR was associated with poorer survival outcomes and lower pCR rates after NACT. However, because of substantial heterogeneity and inconsistent cutoffs, NLR should be viewed as a complementary marker requiring prospective validation rather than a routine prognostic factor.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Zitieren
APA
Zhao, Z., Xu, H., Yuan, H., Ma, B., & Dong, C. (2026). Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1849765
Vancouver
Zhao Z, Xu H, Yuan H, Ma B, Dong C. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1849765
BibTeX
@article{Zhao2026,
author = {Zhao, Ziqian and Xu, Haoyi and Yuan, Hongyi and Ma, Binlin and Dong, Chao},
title = {Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1849765}
}
EUVIMED